The overall goal of this initial stage in developing a Virus Vector Core within the Cancer Center is to promote and coordinate the exchange of information, utilization of expertise, and sharing of virus vector reagents useful for basic virology, gene therapy, and cancer research. The specific objectives are: (1) to maintain, inventory and distribute a library of both standard and custom recombinant adenovirus, AAV, retrovirus, lentivirus, herpesvirus, and sindbis virus vector, including for example, GFP, betaGAL, and LUC expression vectors and related cell lines, and transfer plasmids; (2) to assist investigators in designing and generating specific novel virus vectors for constitutive or inducible expression of foreign genes for basic and clinical research purposes; (3) to provide facilities, expertise, and assistance with moderate scale production and quality control of experimental research grade rAAV and Adenovirus vectors. (4) to provide facilities, reagents and assistance for generation and moderate scale production of quality controlled recombinant retrovirus or lentivirus vectors used for stable transduction of primary mouse and human hematopoietic cells. It is also anticipated that this Core Resource will foster and encourage utilization of the very strong local basic Virology research contingent at Johns Hopkins Medical Institutions for both, firstly, developing collaborative approaches to design and test the much needed new and improved next generation virus vector expression systems, and secondly, promoting interactions with Clinical Research interested in exploiting virus vectors for gene therapy and anti-cancer therapy purposes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-39
Application #
6481447
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications